Quanterix (QTRX) closed at $2.93 on November 13, 2026, up 2.4% from the previous close, on volume of 383,161 shares (30-day average 498,902).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | 4 Leg Call Combo Calendar with Ratio | 19-Feb-27 5|19-Feb-27 2.5|21-May-27 5|21-May-27 2.5[1.5x] C | 225 |
| 2-2 | The next 1 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Quanterix Earnings Call Signals Recovery Amid Execution Risks
TipRanks (Sat, 14-Nov 10:39 PM ET)
TD Cowen Remains a Hold on Quanterix (QTRX)
TipRanks (Tue, 10-Nov 7:56 AM ET)
Canaccord Genuity Sticks to Their Hold Rating for Quanterix (QTRX)
TipRanks (Tue, 10-Nov 7:29 AM ET)
Quanterix Releases Financial Results for the Third Quarter of 2026
Business Wire (Mon, 9-Nov 8:00 AM ET)
Quanterix To Report Third Quarter 2026 Financial Results on November 9, 2026
Business Wire (Wed, 28-Oct 4:30 PM ET)
Market Chameleon (Wed, 7-Oct 7:09 AM ET)
Business Wire (Wed, 7-Oct 8:00 AM ET)
Quanterix Delivers on Spatial Biology Content Innovation Commitments at ESSB 2026
Business Wire (Fri, 25-Sep 8:00 AM ET)
Quanterix Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Wed, 16-Sep 9:00 PM ET)
Quanterix Names Dr. Yuri Fesko Chief Medical Officer
Business Wire (Mon, 14-Sep 8:00 AM ET)
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Quanterix trades on the NASDAQ stock market under the symbol QTRX.
As of November 13, 2026, QTRX stock price climbed to $2.93 with 383,161 million shares trading.
QTRX has a beta of 0.51, meaning it tends to be less sensitive to market movements. QTRX has a correlation of 0.01 to the broad based SPY ETF.
QTRX has a market cap of $139.11 million. This is considered a Micro Cap stock.
Last quarter Quanterix reported $35 million in Revenue and -$.46 earnings per share. This fell short of revenue expectation by $-1 million and missed earnings estimates by -$.08.
In the last 3 years, QTRX traded as high as $29.70 and as low as $2.15.
The top ETF exchange traded funds that QTRX belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
QTRX has underperformed the market in the last year with a return of -44.9%, while SPY returned +13.4%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in QTRX shares. However, QTRX has outperformed the market in the last 3 month and 2 week periods, returning +2.4% and +0.9%, while SPY returned -2.8% and -0.2%, respectively. This indicates QTRX has been having a stronger performance recently.
QTRX support price is $2.70 and resistance is $3.02 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that QTRX shares will trade within this expected range on the day.
